Comparing Calithera Biosciences (NASDAQ:CALA) & Palatin Technologies (PINK:PTNT)

Calithera Biosciences (NASDAQ:CALA) and Palatin Technologies (PINK:PTNT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

11.5% of Palatin Technologies shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Comparatively, 7.1% of Palatin Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Calithera Biosciences has a beta of -2.55, indicating that its share price is 355% less volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Valuation and Earnings

This table compares Calithera Biosciences and Palatin Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65 million	N/A	N/A
Palatin Technologies	$4.49 million	32.44	-$29.74 million	($1.55)	-3.61

Palatin Technologies has higher revenue and earnings than Calithera Biosciences.

Profitability

This table compares Calithera Biosciences and Palatin Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Palatin Technologies	N/A	N/A	-365.57%

Analyst Ratings

This is a breakdown of current recommendations for Calithera Biosciences and Palatin Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calithera Biosciences	0	0	0	0	0.00
Palatin Technologies	0	0	1	0	3.00

Palatin Technologies has a consensus target price of $350.00, indicating a potential upside of 6,150.00%. Given Palatin Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Palatin Technologies is more favorable than Calithera Biosciences.

Summary

Palatin Technologies beats Calithera Biosciences on 8 of the 9 factors compared between the two stocks.

About Calithera Biosciences

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.